Literature DB >> 3756797

Reducing diagnostic delay in breast cancer. Possible therapeutic implications. GIVIO (Interdisciplinary Group for Cancer Care Evaluation) Italy.

.   

Abstract

A detailed examination of the diagnostic process of 1110 newly diagnosed breast cancer patients first seen at 63 Italian general hospitals showed that 36% of them were diagnosed more than 3 months after the appearance of the first symptom. Whereas 17% (108/633) of the women with less than or equal to 3 months delay were Stage III and IV, the corresponding proportion among women with greater than 3 months delay was 32% (101/320), suggesting that 15% of advanced cases can be attributed to diagnostic delay. A 9% gain in survival at 5 years (66% vs. 57%) could be postulated if reported figures on mortality by stage are applied to our patients with less than or equal to 3 months delay compared to those with greater than 3 months. Moreover, examining the two components of delay (first symptom-first visit and first visit-final diagnosis) our data suggest that the potential benefits of timely presentation were, for some patients, cancelled by delays arising in the health care system. Breast self-examination (BSE) was practiced by 34% of the total population, but only 9% did it on a regular monthly basis. Although any type of BSE (regular and irregular) was associated with a smaller primary at presentation, a limited benefit of the procedure in terms of nodal involvement and pathologic stage of disease was evident only among regular BSE performers.

Entities:  

Mesh:

Year:  1986        PMID: 3756797     DOI: 10.1002/1097-0142(19861015)58:8<1756::aid-cncr2820580829>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  What influences diagnostic delay in low-income women with breast cancer?

Authors:  Rose C Maly; Barbara Leake; Cynthia M Mojica; Yihang Liu; Allison L Diamant; Amardeep Thind
Journal:  J Womens Health (Larchmt)       Date:  2011-04-12       Impact factor: 2.681

2.  Do we believe what patients say about their neoplastic symptoms? An analysis of factors that influence the interviewer's judgement.

Authors:  M Porta; N Malats; J Belloc; M Gallén; E Fernandez
Journal:  Eur J Epidemiol       Date:  1996-12       Impact factor: 8.082

3.  Comprehensive diagnostic program for medically underserved women with abnormal breast screening evaluations in an urban population.

Authors:  Frances M Palmieri; Elizabeth R DePeri; Betty A Mincey; Judith A Smith; Lonnie K Wen; Deborah M Chewar; Reza Abaya; Gerardo Colon-Otero; Edith A Perez
Journal:  Mayo Clin Proc       Date:  2009-04       Impact factor: 7.616

4.  Differences between black and white patients with cancer of the uterine corpus in interval from symptom recognition to initial medical consultation (United States).

Authors:  R J Coates; L A Click; L C Harlan; S Robboy; R J Barrett; J W Eley; P Reynolds; V W Chen; W A Darity; R S Blacklow; B K Edwards
Journal:  Cancer Causes Control       Date:  1996-05       Impact factor: 2.506

5.  Quantifying patient preferences for symptomatic breast clinic referral: a decision analysis study.

Authors:  Aisling Quinlan; Kirsty K O'Brien; Rose Galvin; Colin Hardy; Ronan McDonnell; Doireann Joyce; Ronald D McDowell; Emma Aherne; Claire Keogh; Katriona O'Sullivan; Tom Fahey
Journal:  BMJ Open       Date:  2018-05-31       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.